[Antiplatelet therapy after coronary stenting and its importance in total joint arthroplasty].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Transliterated Title:
      Thrombozytenfunktionshemmung nach koronarer Stentimplantation: Bedeutung in der Endoprothetik.
    • Source:
      Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0331266 Publication Model: Print Cited Medium: Internet ISSN: 1433-0431 (Electronic) Linking ISSN: 00854530 NLM ISO Abbreviation: Orthopade Subsets: MEDLINE
    • Publication Information:
      Original Publication: Berlin, New York, Springer-Verlag.
    • Subject Terms:
      Angioplasty, Balloon, Coronary* ; Arthroplasty, Replacement, Hip* ; Arthroplasty, Replacement, Knee* ; Platelet Function Tests* ; Stents*; Coronary Disease/*therapy ; Platelet Aggregation Inhibitors/*adverse effects ; Platelet Aggregation Inhibitors/*therapeutic use ; Postoperative Complications/*drug therapy; Anticoagulants/adverse effects ; Anticoagulants/therapeutic use ; Aspirin/adverse effects ; Aspirin/therapeutic use ; Blood Loss, Surgical ; Comorbidity ; Coronary Disease/blood ; Dose-Response Relationship, Drug ; Drug Substitution ; Drug Therapy, Combination ; Hemorrhage/blood ; Hemorrhage/chemically induced ; Hemorrhage/prevention & control ; Heparin/adverse effects ; Heparin/therapeutic use ; Humans ; Long-Term Care ; Postoperative Complications/blood ; Reoperation
    • Abstract:
      Coronary stenting is an effective treatment for reopening atherosclerotic occlusions of coronary arteries. Depending on the manifestation of coronary artery disease (stable CAD or acute coronary syndrome) and on the type of implanted stent, dual antiplatelet therapy is recommended for a period of 4 weeks to 12 months. In this period total joint replacement is associated with high blood loss and high perioperative morbidity. Therefore antiplatelet therapy is often discontinued and replaced by higher dosages of heparin for prophylactic anticoagulation. However, with this treatment regimen protection of the stent is doubtful and there is a high risk of stent thrombosis with myocardial infarction. The surgery should be scheduled after the dual antiplatelet therapy is replaced by lifelong aspirin therapy. On the other hand, if surgery cannot be postponed perioperative bridging of dual antiplatelet therapy can be conducted to minimize bleeding complications with the best possible stent protection. Lifelong therapy with aspirin should not be discontinued in any case.
    • References:
      Anaesthesist. 2009 Oct;58(10):971-85. (PMID: 19823781)
      N Engl J Med. 2009 Sep 10;361(11):1045-57. (PMID: 19717846)
      Orthopade. 2011 Sep;40(9):774-80. (PMID: 21479616)
      Anesth Analg. 2008 Aug;107(2):552-69. (PMID: 18633035)
      Circulation. 1992 Mar;85(3):916-27. (PMID: 1537128)
      Eur Heart J. 2009 Nov;30(22):2769-812. (PMID: 19713421)
      Eur J Anaesthesiol. 2002 Sep;19(9):647-51. (PMID: 12243287)
      J Invasive Cardiol. 2011 Feb;23(2):44-9. (PMID: 21297198)
      Anaesthesist. 2009 Oct;58(10):969-70. (PMID: 19823780)
      Anesthesiology. 2008 Oct;109(4):573-5. (PMID: 18813033)
      Internist (Berl). 2010 Apr;51(4):533-8. (PMID: 20333345)
      Circ Cardiovasc Interv. 2009 Jun;2(3):213-21. (PMID: 20031718)
      Eur J Anaesthesiol. 2002 Nov;19(11):829-31. (PMID: 12442934)
      Thromb Res. 2009 Mar;123(5):687-96. (PMID: 19007970)
      J Mol Med (Berl). 2011 Jun;89(6):545-53. (PMID: 21279500)
      Int J Cardiol. 2011 Jul 1;150(1):101-3. (PMID: 21497406)
      J Am Coll Cardiol. 2003 Jul 16;42(2):234-40. (PMID: 12875757)
      Am J Cardiol. 1984 Jun 15;53(12):12C-16C. (PMID: 6233874)
      N Engl J Med. 2007 Nov 15;357(20):2001-15. (PMID: 17982182)
      J Intern Med. 2005 May;257(5):399-414. (PMID: 15836656)
      N Engl J Med. 1998 Dec 3;339(23):1665-71. (PMID: 9834303)
      J Arthroplasty. 1988;3 Suppl:S47-9. (PMID: 3199139)
      Circulation. 2007 Feb 13;115(6):813-8. (PMID: 17224480)
      Chirurg. 2009 Jun;80(6):498-501. (PMID: 19011817)
      Eur Heart J. 2010 Oct;31(20):2501-55. (PMID: 20802248)
      Indian J Orthop. 2011 Mar;45(2):148-52. (PMID: 21430870)
      Orthopade. 2011 Feb;40(2):178-82. (PMID: 21246349)
      Rev Cardiovasc Med. 2009 Fall;10(4):209-18. (PMID: 20065931)
    • Accession Number:
      0 (Anticoagulants)
      0 (Platelet Aggregation Inhibitors)
      9005-49-6 (Heparin)
      R16CO5Y76E (Aspirin)
    • Publication Date:
      Date Created: 20120529 Date Completed: 20121107 Latest Revision: 20211021
    • Publication Date:
      20240829
    • Accession Number:
      10.1007/s00132-012-1900-4
    • Accession Number:
      22638598